PureTech Announces Board Change
September 07 2019 - 5:14PM
Business Wire
PureTech Health plc (LSE: PRTC), today announced that Joichi
“Joi” Ito, Ph.D., has stepped down from the board of directors, and
current board member, Chris Viehbacher, will act as interim chair.
“Given circumstances related to the MIT Media Lab, we agreed that
Joi’s resignation from PureTech was appropriate,” said Daphne
Zohar, founder and chief executive officer of PureTech. “We are
pleased to have Chris Viehbacher as our interim chair.”
Christopher Viehbacher is a member of the PureTech Board and
will serve as interim chairman. He is the managing partner of
Gurnet Point Capital. Mr. Viehbacher is the former CEO of Sanofi, a
Paris listed Fortune 50 Biopharmaceutical Company and the former
chairman of Genzyme. Prior to joining Sanofi, Mr. Viehbacher spent
20 years at GlaxoSmithKline, ultimately serving as president of
GSK’s North American pharmaceutical division and as a member of the
board of directors of GSK plc. He began his career with
PriceWaterhouseCoopers LLP and qualified as a chartered accountant
in Canada. Mr. Viehbacher has co-chaired the CEO Roundtable on
Neglected Diseases, an organization that led to over 1.3 billion
people being treated for such diseases free of charge. He was the
chairman of the board of the Pharmaceutical Research and
Manufacturers of America (PhRMA) as well as president of the
European Federation of Pharmaceutical Industries and Associations
(EFPIA). At the World Economic Forum at Davos, he was a chair of
the Health Governors and co-chaired an initiative to create a
Global Charter for Healthy Living. He was also a member of the
International Business Council. Mr. Viehbacher has received the
Pasteur Foundation Award for outstanding commitment to safeguarding
and improving health worldwide. He has also received France’s
highest civilian honor, the Legion d’Honneur. Various awards form
the Thompson Reuters/Excel Investor Survey, including top chief
executive officer and top European company, have recognized his
commitment to investor relations.
About PureTech Health
PureTech is a clinical stage biotechnology company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases, including intractable cancers,
lymphatic and gastrointestinal diseases, central nervous system
disorders, and inflammatory and immunological diseases, among
others. The Company has created a broad and deep pipeline through
the expertise of its experienced research and development team and
its extensive network of scientists, clinicians and industry
leaders. This pipeline, which is being advanced both internally and
through PureTech’s affiliates, is comprised of 24 product
candidates and one product that has been cleared by the US Food and
Drug Administration (FDA). All of the underlying programs and
platforms that resulted in this pipeline of product candidates were
initially identified or discovered and then advanced by the
PureTech team through key validation points based on the Company’s
unique insights into the biology of the brain, immune, and gut, or
BIG, systems and the interface between those systems, referred to
as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190907005029/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
EU media Ben Atwell, Rob Winder +44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
US media Tom Donovan +1 857 559 3397
tom@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024